CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

Inclusion Criteria

• •1. Signed informed consent obtained prior to initiation of any study-specific procedures and treatment;
• •2. Previously treated, pathologically confirmed, locally advanced or metastatic solid tumors with measurable disease for which cisplatin is a reasonable treatment option, including, but not limited to, non-small cell lung, mesothelioma, head \& neck, ovarian, endometrial, breast, bladder, kidney, esophageal, gastric, colon, liver, gallbladder, cholangiocarcinoma, pancreas, soft tissue sarcoma, and osteosarcoma (for the expansion cohorts, only metastatic exocrine pancreatic cancer and microsatellite stable colorectal cancer are allowed). There is no limit on the number of prior lines of chemotherapy (including prior cisplatin), chemoradiotherapy, radiotherapy or investigational agents the patient can have received in order to be eligible, as long as cisplatin is a reasonable treatment option and all eligibility criteria are met, with the exception that a patient must not have received more than two prior lines incorporating anti-PD-1, anti-PD-L1, or anti-CTLA-4 immune checkpoint blockade.
• •Patients who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4 immune checkpoint blockade therapy must have tolerated therapy with no evidence of grade 4 toxicity or an immune-related event (any grade) that required treatment discontinuation. Patients who experienced an endocrine related dysfunction are eligible, provided they are on stable hormone replacement therapy;
• •3. Male or female patients aged ≥ 18 years at time of informed consent;
• •4. ECOG Performance Status (PS) 0-1;
• •5. Life expectancy \> 3 months;
• •6. Previous anticancer treatment must be discontinued at least 3 weeks prior to the initiation of study treatment (6 weeks for mitomycin C; 6 weeks for anti-androgen therapy if discontinued prior to treatment initiation, except 8 weeks for bicalutamide);
• •7. Adequate bone marrow reserve, cardiac, liver, renal and metabolic function:
• •* absolute neutrophil count (ANC) ≥ 1.5 x 109/L;
• •* platelet count ≥ 100 x 109/L;
• •* hemoglobin ≥ 9 g/dL;
• •* white blood cell count (WBC) ≤ upper limit of normal (ULN);
• •* creatinine phosphokinase isozymes CPK-MB and CPK-MM
• •≤ ULN;
• •* serum troponin T levels within normal limits;
• •* bilirubin ≤ 1.5 x ULN;
• •* alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases are present);
• •* INR ≤ 1.5 x ULN;
• •* serum creatinine ≤ ULN or creatinine clearance ≥ 60 mL/min (by Cockroft \& Gault formula or alternate calculation by 24hr urine collection);
• •* serum potassium NCI-CTCAE version 4.03 Grade \<2;
• •* serum calcium NCI-CTCAE version 4.03 Grade \<2;
• •* serum magnesium NCI-CTCAE version 4.03 Grade \<2;
• •8. Female patients of child-bearing potential must have a negative serum pregnancy test and use at least one form of contraception as approved by the investigator for 4 weeks prior to initiating study treatment and 4 months after the last dose of study drug. For the purposes of this study, child-bearing potential is defined as "all female patients unless they are post-menopausal for at least 3 years or surgically sterile";
• •9. Male patients must use a form of barrier contraception approved by the investigator during the study and for 4 months after the last dose of study drug;
• •10. Ability to cooperate with study treatment and follow-up.
• •11. Who require chronic systemic steroid therapy or on any other form of immunosuppressive medication;
• •12. Has received a live-virus vaccination within 30 days of planned treatment start;
• •13. With known risk factors for bowel perforation, i.e., history of diverticulitis, intra-abdominal abscess, intestinal obstruction, or abdominal carcinomatosis;
• •14. Has an active autoimmune disease or a documented history of autoimmune disease;
• •15. Has a history pneumonitis or interstitial lung disease.